GNI agrees ex-China pirfenidone deal with AFT
This article was originally published in Scrip
Executive Summary
GNI Group has struck a deal with the New Zealand-based company AFT Pharmaceuticals for the commercialization of the idiopathic pulmonary fibrosis drug Etuary (pirfenidone/F647) in a number of selected markets outside China.